54.03
-0.96 (-1.75%)
| Penutupan Terdahulu | 54.99 |
| Buka | 55.28 |
| Jumlah Dagangan | 83,903 |
| Purata Dagangan (3B) | 670,833 |
| Modal Pasaran | 1,599,746,176 |
| Harga / Jualan (P/S) | 6.49 |
| Harga / Buku (P/B) | 124.01 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Aug 2026 |
| Margin Keuntungan | -125.70% |
| Margin Operasi (TTM) | -99.16% |
| EPS Cair (TTM) | -4.76 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 286.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1,016.89% |
| Nisbah Semasa (MRQ) | 8.25 |
| Aliran Tunai Operasi (OCF TTM) | -108.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.04 M |
| Pulangan Atas Aset (ROA TTM) | -15.14% |
| Pulangan Atas Ekuiti (ROE TTM) | -343.83% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | AnaptysBio, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.83 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.09% |
| % Dimiliki oleh Institusi | 133.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ecor1 Capital, Llc | 31 Mar 2026 | 7,880,094 |
| Sanofi | 30 Jun 2026 | 821,917 |
| Palo Alto Investors Lp | 31 Mar 2026 | 638,161 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |